×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
GlobeNewswire
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company...
13 hours ago
Minerva Neurosciences falls as US FDA declines to approve drug for schizophrenia symptoms
Reuters
Minerva Neurosciences said on Tuesday the U.S. Food and Drug Administration (FDA) has declined to approve its drug to regulate behavioral...
2 months ago
NERV Stock Earnings: Minerva Neurosciences Beats EPS for Q1 2024
MSN
Minerva Neurosciences (NASDAQ:NERV) just reported results for the first quarter of 2024. Minerva Neurosciences reported earnings per share of -$1.13.
7 hours ago
Minerva Neurosciences (NERV) Reports Q2 Loss, Lags Revenue Estimates
Yahoo Movies UK
Minerva Neurosciences (NERV) delivered earnings and revenue surprises of -47.06% and -100.00%, respectively, for the quarter ended June 2021...
3 days ago
Minerva's schizophrenia drug rejected by FDA for 2nd time
Fierce Biotech
Perhaps Minerva Neurosciences should have taken a page from the tale of Arachne: Never boast that you know better than the goddess of...
2 months ago
5 FDA Decisions to Watch in Q1
BioSpace
Iovance's lifileucel for advanced melanoma and Madrigal's resmetirom for nonalcoholic steatohepatitis are just a couple of the key decisions...
3 months ago
NERV Stock Quote Price and Forecast
CNN
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product...
1 month ago
Minerva Neurosciences (NASDAQ:NERV) Stock Crosses Below 200 Day Moving Average of $5.57
Defense World
Read Minerva Neurosciences (NASDAQ:NERV) Stock Crosses Below 200 Day Moving Average of $5.57 at Defense World.
1 week ago
Minerva mauled over roluperidone CRL
The Pharma Letter
CNS specialist Minerva Neurosciences (Nasdaq: NERV) lost 59% of its stock market value on Tuesday. Investors were reacting to the news that...
2 months ago
Another setback for Minerva's schizophrenia treatment roluperidone
Clinical Trials Arena
To manoeuvre past the clinical deficiencies stated in the recent CRL, Minerva must provide additional safety and efficacy data for...
2 months ago